CLX · sample dossier
CLX
41/100
OutdatedGenerated Aug 8, 2026 · 10:15 PM UTC · 89 days ago
This copy is frozen (Aug 8). Sign in to run the same work — filings, valuation, bull and bear, sources — on any US stock or ETF, in about 90 seconds.
Run a fresh dossierCLX
EquityPublic company
Decision context
Recommendation
Balanced between moderate Quality (52/100) and constrained Growth (23/100).
A mixed picture — no strong reason to buy or sell right now.
AlphaDog Fair Value
Executive thesis & key metrics
Executive Investment Thesis
The Clorox Company (CLX) is a consumer products manufacturer trading at $105.15 with fiscal year 2026 net sales of $6.7 billion and a P/E ratio of 21.86. A Hold verdict fits given stagnant growth, with revenue growth YoY at 0.1% and EPS growth YoY at 2.7%, alongside an EV/EBITDA multiple of 15.21. The single biggest balance sheet risk is a Debt/Equity ratio of 21.90 alongside a 1-year return of -15.8%.
Key Metrics to Watch
What changed recently
No material changes found in the last 30 days.
Why this rating
Score 41 · Hold
Data through
OutdatedMar 31, 2026
Composite 41/100 — no single factor above 75 dominates.
Levels unavailable — AlphaDog quantitative valuation model did not produce an estimate from comps or DCF
Re-evaluate if
- Net margin drops below current 8.7% baseline
- YoY revenue growth below current 0.1% baseline
- Revenue growth YoY falls below 0.1%
Trim / reconsider if
- ROA falls below 6.0% (was 9.2%)
- Gross margin compresses below 40.0%
- Gross margin falls below 40.0% or net margin falls below 5.0%
Dollar levels aren’t available for this run — the view above still stands.
A Calmer Look · Devil's Advocate
The market consensus treats Clorox as a safe defensive 'Hold' trading at 21.9x P/E and 15.2x EV/EBITDA, dramatically underestimating severe balance sheet leverage and operational friction.
May be overlooked
Grey-zone distress risk ignored by momentum chasers
An Altman Z-Score of 1.99 places CLX in financial danger, yet consensus focuses on moving averages while ignoring a Debt/Equity ratio of 21.90.
Persistent ERP rollout and manufacturing friction
FY2026 diluted EPS declined 26% YoY due to ERP disruptions and logistics costs, exposing operational fragility that consensus assumes will vanish near-term.
Capital efficiency degradation
An ROA of 9.2% coupled with 0.1% YoY revenue growth indicates that incremental capital deployment is failing to generate top-line expansion.
Expectations look stretched
Unsubstantiated GOJO M&A expectations
Assuming the April 2026 GOJO acquisition seamlessly expands B2B revenue ignores integration costs after a year where diluted EPS fell 26%.
Multiple inflation on declining earnings
A P/E of 21.9 and P/B of 141.9 reflect valuation expansion driven by price bounce (+13.0% in 1M) rather than fundamental earnings recovery.
Overvaluing gross margin relative to net bottom line
Celebrating a 42.8% gross margin ignores net margin compression down to 8.7% under manufacturing cost pressures.
Revenue growth YoY falls below 0.1%
Revenue growth YoY falls below 0.1%
Market context
Snapshot returns at report publication
1 month
+13.0%
3 months
+14.2%
6 months
-10.6%
1 year
-15.8%
At a Glance
This company is on a steady trend at fair pricing.
Top Holders
Go deeper
For learning and research only — not investment advice. AlphaDog doesn’t hold stocks and isn’t your financial advisor.
Run the next one yourself.
You just read a full CLX dossier — scored verdict, valuation, and both sides, with sources. Sign in to run that on a name you hold, on current filings. A free account includes 10 credits a week, 1 per fresh run.